Classifications

• • G—PHYSICS
  • G01—MEASURING; TESTING
  • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
  • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
  • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
  • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
  • G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
  • G01N33/585—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with a particulate label, e.g. coloured latex

Definitions

• immunologically-based assays Infectious, acute, and chronic diseases of humans, animals, and plants can be diagnosed or detected using immunologically-based assays.
• a variety of such procedures are known, and include the so-called “sandwich” immunoassays, the competitive binding assays, and others, that can be employed to determine the presence or absence of a molecule of interest in fluid or non fluid samples.
• a common feature of immunoassays is that they are based on the specificity of antigen-antibody reactions. This specific reaction gives rise to what is denominated an immunocomplex.
• the antibodies also known as immunoglobulins
• the antibodies can be of polyclonal or monoclonal origin, and act as specific binding partners for particular antigens, being the latter molecules with single or multiple epitopic sites.
• Immunoassays are also characterized by the presence of some kind of labelling procedure that allows the identification of an antigen-antibody reaction.
• the labelling can be part of this antigen-antibody reaction, or constitute an additional step in the assay. In the latter case, labelling involves an additional specific recognition of either the antigen or antibody in the immunocomplex by an additional molecule bearing a marker substance.
• markers are currently employed in immunoassays (radioactive isotopes, metal and non-metal particles that can agglutinate, substances that can be activated for light emission, or that can give rise to colored soluble or insoluble reactions. etc.).
• Leuvering (U.S. Patent No. 4,313,734), describes a new immunoassay procedure involving the use of colloidal metal substances. While such colloids are employed as labels in immunological conjugates, the procedure is dependent upon the use of spectrophotometers for the identification of the presence of the colloidal metal, after it has been chemically extracted from the site of the immunological reaction. The assay thus relies on cumbersome preliminary extraction procedures, and expensive auxiliary instrumentation, in order to obtain relatively insensitive results.
• EP 158,746, assigned to Janssen describes an immunoassay procedure based on the diffusion of reagents on membrane matrix surfaces (immunobloting techniques). While providing a better alternative over that of Leuvering, the described method still suffers from excessive execution time and stages, including the previous preparation and blocking of the membranes.
• Janssen takes into consideration existing knowledge about the use of physical developers based on the reduction of silver ions, for the visualization of insoluble metals in tissues (Danscher, Histochemistry 71:1-16, 1981), and the use of colloidal gold particle conjugates in histological staining, that are afterwards amplified with similar developers (Holgate et all. J. Histochem. Cytochem. 31,938-944, 1983), and provide a way to obtain higher sensitivity than the original method of immunostaining with colloidal gold conjugates.
• Janssen describes the additional use of physical developers, insensitive to light and conformed by two separate solutions, in his procedure, as a way to improve sensitivity and visual characteristics of the assays based on membrane matrixes.
• the membrane matrixes require previous steps of preparation and blocking, and the use of a special individual device for each sample, composed of the said membrane, absorbent material, and a conformed plastic body, leads an increase in cost and technological complexity in production.
• the present invention relates to the immunoassay methods and specially, with a new immunoassay system that detects immunologically active molecules in fluid samples.
• Such molecules can be single or monoepitopic antigens, or antibodies.
• the specific recognition between antigens and antibodies creates an indistinctive ligand-ligand binding partner pair, the latter terms will be hereafter used indistinctively in the text. These terms will also be used to describe the reaction between a labelled substance and the immunocomplexes.
• the present invention has as object a new assay procedure, that uses opaque white plastic supports with delimited reaction areas, coated with a ligand binding partner.
• the immunological reaction takes place when the sample is incubated in such areas, and the specific binding partner coated to the plastic support reacts with the ligand present in the sample.
• the labelling of such reaction is made possible using conjugates of monodisperse colloidal gold particles and a specific binding partner for the ligand in the sample.
• the colloidal gold particles have a preferred diameter range between 1 and 18 nanometers, and the conjugate an absorbance value between 0.5 and 1.15, measured at a wave length of 520-540 nanometers.
• the visualization of the reaction is made after a final step where the signal produced by the deposition of the colloidal gold is amplified by physical developers, based on silver ions. This amplification gives rise to a metallic darkish-black color, that contrasts with the white plastic support.
• the new immunoassay system involves:
• this immunoassay procedure is one of easy preparation, execution, reagent economy, high sensitivity and specificity levels, and that can be adequated to formats that assure the inclusion of true negative and positive sample controls in each experiment.
• the procedure can be adapted to "sandwich", competitive binding, or other types of assays, for the detection of either antigens or antibodies in fluid sample.
• Such immunoassays can be produced economically, with the necessary quality requirements of batch production.
• Another advantage of the procedure proposed in this invention is that it gives rise to immunoassays that can be fully interpreted in a visual manner, without the need of additional equipment.
• Another aspect of the present invention is the possible extension of the nature of the support to several plastic substances of varying polymeric structure as polystyrene, polyamide, polycarbonate, polyvinyl chloride, and others, that mixed in the stage of raw material, and in adequate proportion, with chemical compounds of titanium, zinc and others, result in opaque supports that can be casted in different final formats.
• surface treatments including those similar to the ones conventionally employed in the production of microtiter well plates and strips for enzyme linked immunosorbent assays (ELISA) techniques, it is possible to optimize the coating of the plastic surfaces for a variety of ligands, either by adsorption, or covalent linkage.
• the new immunoassay procedure is useful for the detection of a wide variety of ligands in fluid samples, such as total blood, serum, plasma, urine, saliva, and others.
• Specific antigens of, or antibodies to, viral entities human immunodeficiency viruses, hepatitis C and B viruses, cytomegalovirus, rotavirus, etc.
• bacteria and parasites can be detected.
• Ligands of different nature to the ones described above, i.e. other biological and non-biological molecules, can also be detected using immunoassays constructed on the principles of the present invention.
• the assay uses opaque white polystyrene supports, with delimited polished circular reaction areas, where a ligand binding partner is coated.
• the details of the procedure depend on the type of assay, whether this be a direct, competitive, or "sandwich"-type of assay.
• the immunological reaction is produced when the support is incubated with the sample, that contains a ligand specific for the binding partner coated to the plastic surface.
• a successive incubation with a conjugate of colloidal gold and binding partner for the ligand (sandwich-type) follows.
• this step is unnecessary, as the sample is incubated with the coated plastic surface, together with a conjugate of colloidal gold and the ligand of interest.
• a final step in the method involves the incubation of the plastic surfaces with a mixture of liquid reagents that give rise to a physical developer containing silver ions, able to amplify the final detection of the colloidal gold particles. Washing steps after each incubations ensure the elimination of the excess of ligands and unspecific molecules present in the sample, of unbound conjugate, and physical developers solution.
• the present invention has shown that the combination of polished plastic surfaces of opaque white color, and the use of colloidal gold conjugates, followed by physical developers, can result in very simplified, yet highly sensitive immunoassay procedures, of acceptable operational speed (around 60 minutes of total assay time), and allowing a visual reading of results.
• the signal amplification is due to the formation of a highly contrasting metallic darkish-black color that develops when the gold particles, specifically linked to the plastic surface by the immunological reaction, induce the reduction of the silver ions to the corresponding metal, that deposits in a proportional and controlled fashion around the gold particles.
• This amplification makes possible the visualization of the reaction in cases where the ligand concentration in the sample is very low.
• the sensitivity and specificity levels obtained through the said procedure are comparable with those reported for conventional immunoenzymatic techniques (ELISA).
• immunoassays intended for the detection of antibodies (now the ligand) against known pathogens (serologic diagnosis) in fluid sample, are some of procedures that can be developed using the principles described in this invention.
• immunoassays intended for the detection of antibodies (now the ligand) against known pathogens (serologic diagnosis) in fluid sample, are some of procedures that can be developed using the principles described in this invention.
• using a mixture of recombinant proteins representative of the envelope gp 120 and gp41 antigens, and the core gag24 protein of the human immunodeficiency virus (HIV-1), produced by the Center for Genetic Engineering and Biotechnology of Havana, Cuba we have developed a "sandwich" format that allows the serological detection of IgG antibodies to HIV-1 in samples from seropositive subjects.
• the preparation of the said recombinant proteins is a known art and has not to be described here.
• IgG, IgA, and IgM to Toxoplasma gondii IgG and IgM to Rubella
• IgG and IgM to Cytomegalovirus IgG and IgM to Leptospira
• IgG to Hepatitis C virus IgG to Hepatitis B virus
• IgG and IgM to Treponema pallidum etc.
• binding partners can be monoclonal or polyclonal antibodies specific to IgG, IgA or IgM, protein A, protein G, or any other immunoglobulin-specific binding partner.
• the employed conjugate was constructed by coupling the colloidal gold particles and recombinant protein A. Recombinant protein A is produced by the Center for Genetic Engineering and Biotechnology of Havana, Cuba, and its preparation is a known art. Consequently it was considered unnecessary a detailed description.
• This reagent is an example of a ligand able to specifically recognize and bind to the Fc region of several immunoglobulins, among them, the human IgG (Romano et al. Immunochemistry 14:711, 1977).
• colloidal gold particles are conjugated with other monoclonal and polyclonal antibodies that identify either similar or different epitopes of the antigen that has been "captured" by the ligand binding partner coated to the plastic surface.
• the final step of the assay i.e. the amplification of the signal with physical developers, is similar to what has been described above.
• Another advantage of this invention over previous methods is that the amount of sample that has to be employed for the assay is very small.
• the size of the circular delimited reaction areas in the plastic support can be made of a diameter such that only 20-30 microliters of diluted blood, plasma, serum, urine, etc., has to be applied.
• the inventors have found that even with delimited areas of as little as 7 mm of diameter the reaction can be readily visualized, with the required sensitivity levels, in "sandwich"-types of assays.
• conjugates prepared with colloidal gold particles of diameter ranging between 1 and 18 nanometers diluted to an optimal absorbance value of 1 at a wave length of 520-540 nm, low sample volumes as those referred (20-30 microliters), and short incubation times at room temperature for sample (5-30 minutes), conjugate (5-30 minutes), and physical developers (5-15 minutes) were enough to achieve high sensitivity levels.
• the best physical developers are the light insensitive ones of the type described by the European Patent Application EP 29,397 assigned to Janssen.
• the assay is finalized by applying over the reaction areas an equal part mixture of a reagent A, containing silver ions stabilized in a transparent solution, and a reagent B, containing the developer in itself, also in a transparent solution.
• a reagent A containing silver ions stabilized in a transparent solution
• a reagent B containing the developer in itself, also in a transparent solution.
• the mixture of reagents A and B will conserve its transparency for a prolonged time, under environmental light. No color will thus develop in the reaction areas.
• the procedure described in the present invention can also be adapted to cases where "sandwich"-types of format cannot be developed, due to the absence of multiple epitopic sites in the substance of interest (i.e. drugs, hormones, chemical compounds, etc.). For such situations, competitive assays can be developed; the plastic support is coated with a specific ligand binding partner (i.e. monoclonal or polyclonal antibodies, etc.), and the sample presumably containing the ligand is placed in contact with the reaction areas, simultaneously with a conjugate of such ligand and colloidal gold.
• a specific ligand binding partner i.e. monoclonal or polyclonal antibodies, etc.
• the procedure object of the present invention can give rise to an immunoassay that can be packed as a diagnostic/detection kit containing the precoated opaque white plastic supports, a vial with the colloidal gold conjugate, the vials with the solutions for the preparation of the physical developer, flasks with the necessary dilution and wash buffers, vials with true positive and negative controls, instruction sheet, and ancillary materials (spare vials, disposable pipettes, etc.).
• the format of the plastic support can be adapted to various requirements, as, for example, for multiple tests (slide-like supports with several reaction areas, or any other convenient geometry), or for a single-test assay.
• the present invention can be applied in combination with adequate instrumentation to develop a quantitative assay, based on densitometric reading, or using sensors specific for the involved metallic substances.
• All the glass surfaces that contact the colloidal gold solution, or the components for its preparation, should be silanized using a 2% dimethylchlorosilane solution (Merck) in chloroform (Fluka), and a 20 minute immersion, followed by successive washes in absolute ethanol and distilled water.
• a 1% gold chloride (Aldrich) solution prepared in a final volume of 1 liter of Milli-Q (Millipore Inc.) water, is heated to 100oC for 10 minutes.
• Forty ml of a mixture of trisodium citrate and 1% tannic acid, as reducing agent are added to the reactor. After a boiling period of approximately 5-10 minutes, the formation of the colloidal gold solution occurs, indicated by the successive changes in color.
• the reactor is then slowly cooled at room temperature.
• the average diameter of the colloidal gold particles produced under such conditions varies between 10 and 15 nanometers, and the monodisperse character and homogeneity were determined using transmission electron microscopy (100 kV, 50,000x) employing hydrophilic mesh with Formvar-carbon membranes.
• the pH of the colloidal solution is adjusted with the addition of 0.1 M K2CO3.
• the pH value is adjusted in the 6.0-6.5 range.
• the pH range should be 7.0-7.5.
• the isoelectric point of each particular molecule should be taken into account.
• the optical density of the colloidal suspension is measured at a wave length of 520-540 nanometers.
• Example 2 Coupling of ligands to colloidal gold
• Salt-free recombinant protein A was diluted with a 0.005 M solution of NaCl, to a concentration of 1 mg/ml.
• the "gold number” that is to say, the amount of protein A necessary to stabilize 100 ml of colloid, was determined by serial dilution of the protein in fixed volumes of colloidal suspension.
• the optimal concentration of recombinant protein A was calculated as the minimal necessary concentration, plus a 10% excess, to stabilize 1 liter of colloidal gold.
• PEG 20,000 Fluka
• Fluka 5% glycerol
• the supernatant was discarded and the pellet washed twice in the 5% glycerol gradient, suspended in a 1:10 ratio with respect to the starting colloidal gold concentration, and filtered through a 0.45 m membrane (Sartorius).
• the final conjugate concentration was adjusted at a OD of 1 (wave length of 540 nanometers) using 0.1 M phosphate buffer, pH 7.4, containing 1% RIA grade bovine serum albumin (BSA; BDH), and 0.05 M sodium azide (Merck).
• BSA bovine serum albumin
• Merck 0.05 M sodium azide
• Procedure 1 Preparation of the physical developer, sensitive to environmental light
• Solution A is prepared in a volume of 100 ml of deionized water, by adding the following components:
• the physical developer is prepared by mixing the total of both solutions A and B, in conditions protected from environmental light.
• Procedure 2. Preparation of a system of physical developer, insensitive to environmental light
• Solution A is prepared in a 100 ml volume of distilled and deionized water, with the following components:
• Solution B is prepared in a 100 ml volume of distilled and deionized water, with the following components:
• Both solutions are separately stored between 2 and 4oC and maintain their transparency and stability to environmental light for periods of time up to 12 months.
• the preparation of the physical developer is made just before its use. Equal amounts of solutions A and B are mixed at room light and temperature conditions, for a final volume enough to cover the circular delimited reaction areas in the plastic supports of the aforementioned examples, and incubated for 10 minutes at room temperature. In the presence of the small gold particles, the silver ions of the developing solution are capable of reducing to the corresponding metal, and nucleate surrounding the gold particles, to form metallic precipitates of darkish-black color. This amplification effect of the signal increases considerably the contrast, without unspecific background effects, and thus, confers to the method a high level of sensitivity.
• Example 5 Assay for the detection of antibodies against the human immunodeficiency virus type 1 (HIV-1)
• the low-depth wells are sensitized with a mixture of recombinant proteins representative of antigenic domains of the envelope gp120 and gp41 proteins, and the core gag24 proteins of HIV-1 (the recombinant proteins are produced in E. Coli in the Center for Genetic Engineering and Biotechnology of Havana, Cuba).
• the recombinant proteins are diluted in a carbonate-bicarbonate buffer, pH 8.0.
• Each well is coated with 50 l of the mixture in concentrations ranging from 1 to 20 g/ml, for 3 hours, at 37oC.
• the supports are washed with PBS-0.05% Tween 20 and 0.1% of sodium azide to remove the excess of non adsorbed protein, dried, and stored between 2-4oC, protected from humidity with desiccant.
• Each sample was diluted 1:10 with a dilution buffer containing 0.1 M PBS, 0.05% M Tween 20, 0.1% sodium azide, and 0.5% diethanolamine.
• Example 6 Assay for the simultaneous detection of IgG, IgM, and IgA antibodies to Toxoplasma gondii
• the supports were used according to Procedure 1 of Example 4 (3-well strip format; see enclosed annex with drawings).
• the supports were sensitized in similar conditions to the ones described in Procedure 1 of Example 5, but using as antigen a lysate containing membrane and cytoplasmic proteins of the trophozoite of Toxoplasma gondii, obtained from the ascitic fluid of BALB/c mice, inoculated with the RH strain.
• the samples were preadsorbed with appropriate amounts of a desiccated Protein A-sepharose gel, so as to remove competitive effects of specific IgG antibodies.
• the sheep antibodies, purified by affinity chromatography, were obtained in the Center for Genetic Engineering and Biotechnology of Havana, Cuba, and the coupling method was the one described in Example 2 for covalent binding.

Landscapes

• Life Sciences & Earth Sciences (AREA)
• Health & Medical Sciences (AREA)
• Engineering & Computer Science (AREA)
• Molecular Biology (AREA)
• Biomedical Technology (AREA)
• Chemical & Material Sciences (AREA)
• Hematology (AREA)
• Immunology (AREA)
• Urology & Nephrology (AREA)
• Cell Biology (AREA)
• Microbiology (AREA)
• Biotechnology (AREA)
• Food Science & Technology (AREA)
• Medicinal Chemistry (AREA)
• Physics & Mathematics (AREA)
• Analytical Chemistry (AREA)
• Biochemistry (AREA)
• General Health & Medical Sciences (AREA)
• General Physics & Mathematics (AREA)
• Pathology (AREA)
• Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
• Investigating Or Analysing Biological Materials (AREA)

Priority Applications (3)

Applications Claiming Priority (3)

Publications (1)

Family

ID=27169577

Family Applications (1)

Country Status (3)

Cited By (19)

Families Citing this family (2)

Citations (7)

Family Cites Families (1)

• 1993
  • 1993-09-03 CA CA002105515A patent/CA2105515A1/fr not_active Abandoned
  • 1993-09-14 EP EP93500124A patent/EP0643307A1/fr not_active Withdrawn
  • 1993-09-30 JP JP5245382A patent/JPH07120470A/ja active Pending

Patent Citations (7)

Non-Patent Citations (1)

Also Published As

Similar Documents

Legal Events